AbCellera Biologics Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| Basic and diluted loss per share | 2023 | 2024 | 2025 | ||||||||||||||
| Net loss | $ | (146,398) | $ | (162,857) | $ | (146,412) | |||||||||||
| Weighted-average common shares outstanding | 289,166,486 | 294,327,532 | 298,707,082 | ||||||||||||||
| Net loss per share - basic and diluted | $ | (0.51) | $ | (0.55) | $ | (0.49) | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2022 | Feb 21, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.